Moderna and Merck’s personalised cancer vaccine intismeran met its primary endpoint in a 1,137-patient Phase 3 melanoma trial on August 19, sending Moderna shares up 177% and marking the first late-stage mRNA cancer vaccine success.
Moderna and Merck’s personalised cancer vaccine intismeran met its primary endpoint in a 1,137-patient Phase 3 melanoma trial on August 19, sending Moderna shares up 177% and marking the first late-stage mRNA cancer vaccine success.